中文名 | N-[(1,2-二氢-6-甲基-2-氧代-4-丙基-3-吡啶基)甲基]-1-(1-甲基乙基)-6-[6-[4-(1-甲基乙基)-1-哌嗪基]-3-吡啶基]-1H-吲唑-4-甲酰胺 |
---|---|
英文名 | N-[(6-methyl-2-oxo-4-propyl-1H-pyridin-3-yl)methyl]-1-propan-2-yl-6-[6-(4-propan-2-ylpiperazin-1-yl)pyridin-3-yl]indazole-4-carboxamide |
英文别名 |
s7165
1-Isopropyl-6-[6-(4-isopropyl-1-piperazinyl)-3-pyridinyl]-N-[(6-methyl-2-oxo-4-propyl-1,2-dihydro-3-pyridinyl)methyl]-1H-indazole-4-carboxamide unc1999 1H-Indazole-4-carboxamide, N-[(1,2-dihydro-6-methyl-2-oxo-4-propyl-3-pyridinyl)methyl]-1-(1-methylethyl)-6-[6-[4-(1-methylethyl)-1-piperazinyl]-3-pyridinyl]- |
描述 | UNC1999 是一种有效,选择性和SAM-竞争性的 EZH2 和 EZH1 抑制剂,IC50 分别为 10 nM 和 45 nM。 |
---|---|
相关类别 | |
靶点 |
IC50: <10 nM (EZH2), 45 nM (EZH1)[1] |
体外研究 | UNC1999,第一种口服生物可利用的抑制剂,对野生型和突变型EZH2以及EZH1具有高体外效力,EZH1是一种密切相关的H3K27甲基转移酶,在各自的催化结构域中与EZH2具有96%的序列同一性。 UNC1999对EZH2和EZH1具有高选择性,适用于广泛的表观遗传和非表观遗传靶标,与辅因子SAM竞争,与肽底物无竞争性。对于sigma1,sigma2,组胺H3和NET(去甲肾上腺素转运蛋白),UNC1999的Ki值分别为4,700 nM,65 nM,300 nM和1,500 nM。 NC1999选择性地杀死DB细胞,即具有EZH2 Y641N突变的DLBCL细胞系。 UNC1999显示DB细胞增殖的浓度和时间依赖性抑制(EC50 = 633±101nM(n = 3))[1]。 |
体内研究 | 以15,50或150mg/kg单次腹膜内(IP)注射UNC1999获得高C max(9,700-11,800nM)并且在雄性瑞士白化小鼠中表现出剂量线性。在整个24小时内,150和50mg/kg IP剂量均导致UNC1999的血浆浓度高于其细胞IC50,而15mg/kg IP剂量导致UNC1999的血浆浓度高于其细胞IC50约12小时。 。我们接下来检查了UNC1999是否是口服生物可利用的,并且很高兴地发现单个50mg/kg口服剂量的UNC1999在雄性瑞士白化小鼠中达到高Cmax(4,700nM)和良好的暴露水平。在单次口服剂量后,UNC1999的血浆浓度维持在其细胞IC50以上约20小时。值得注意的是,所有测试小鼠都能很好地耐受包括150 mg/kg IP剂量在内的所有剂量,并且没有观察到不良反应[1]。 |
激酶实验 | 产生EZH2 Y641N突变体并通过BPS Bioscience进行测定。在HMT测定缓冲液中用10%DMSO制备一系列UNC1999稀释液,并将5μL稀释液加入到50μL反应中,使得DMSO的最终浓度在所有反应中均为1%。所有酶促反应在室温下一式两份进行60分钟(EZH2)和180分钟(EZH2 Y641N)在含有HMT测定缓冲液,S-腺苷甲硫氨酸,酶和UNC1999的50μL混合物中进行。这些50μL反应在HMT基底预涂板的孔中进行。酶促反应后,弃去反应混合物,用TBST缓冲液洗涤每个孔三次,并用封闭缓冲液缓慢摇动10分钟。将孔清空,并加入100μL稀释的1°抗体。然后将板在室温下缓慢摇动60分钟。如前所述,将板清空并洗涤三次,并在室温下与封闭缓冲液一起摇动10分钟。弃去封闭缓冲液后,加入100μL稀释的2°抗体。然后将板在室温下缓慢摇动30分钟。如前所述,将板清空并洗涤三次,并在室温下与封闭缓冲液一起摇动10分钟。弃去封闭缓冲液,新制备HRP化学发光底物的混合物。将100μL该混合物加入每个空孔中。立即,在BioTek SynergyTM 2酶标仪[1]中测量样品的发光。 |
细胞实验 | DB细胞是一种含有EZH2 Y641N突变的弥漫性大B细胞淋巴瘤细胞系,来自ATCC,并在补充有10%胎牛血清,抗生素和各种浓度的UNC1999(0.1,0.2,0.3, 0.4,0.5,1,2,3和5μM)或UNC2400和DMSO对照。含有试验化合物或对照的培养基每三天更新一次。使用TC20自动细胞计数器系统测量来自至少三次独立实验的活细胞数。使用酸性提取方案从细胞核制备总组蛋白。使用15%的SDS-PAGE分离约1微克的总组蛋白,转移至PVDF膜,并用组蛋白抗体探测。本研究中使用的抗体是针对EZH2,一般H3和H3K27me3的抗体[1]。 |
动物实验 | 小鼠[1]使用Sai Life Sciences的雄性瑞士白化小鼠进行标准PK研究。评估UNC1999的四个剂量(15,50和150mg / kg IP,和50mg / kg PO)。每项研究持续24小时。在八个时间点(给药后0.08,0.25,0.5,1,2,4,8和24小时)中报告的UNC1999的血浆浓度是来自3只试验动物的平均值。 |
参考文献 |
密度 | 1.2±0.1 g/cm3 |
---|---|
沸点 | 804.7±65.0 °C at 760 mmHg |
分子式 | C33H43N7O2 |
分子量 | 569.740 |
闪点 | 440.4±34.3 °C |
精确质量 | 569.347839 |
PSA | 99.41000 |
LogP | 4.17 |
外观性状 | white to beige |
蒸汽压 | 0.0±2.9 mmHg at 25°C |
折射率 | 1.643 |
储存条件 | 2-8°C |
水溶解性 | DMSO: soluble15mg/mL, clear |
SECTION 1: Identification of the substance/mixture and of the company/undertaking Product identifiers Product name: UNC1999 REACH No.: A registration number is not available for this substance as the substance or its uses are exempted from registration, the annual tonnage does not require a registration or the registration is envisaged for a later registration deadline.
CAS-No.: 1431612-23-5 Relevant identified uses of the substance or mixture and uses advised against Identified uses: Laboratory chemicals, Manufacture of substances SECTION 2: Hazards identification Classification of the substance or mixture Classification according to Regulation (EC) No 1272/2008 Acute toxicity, Oral (Category 4), H302 For the full text of the H-Statements mentioned in this Section, see Section 16. Classification according to EU Directives 67/548/EEC or 1999/45/EC Xn HarmfulR22 For the full text of the R-phrases mentioned in this Section, see Section 16. Label elements Labelling according Regulation (EC) No 1272/2008 Pictogram Signal wordWarning Hazard statement(s) H302Harmful if swallowed. Precautionary statement(s)none Supplemental Hazardnone Statements Other hazards - none SECTION 3: Composition/information on ingredients Substances Synonyms: 1-Isopropyl-6-(6-(4-isopropylpiperazin-1-yl)pyridin-3-yl)-N-((6-methyl-2- oxo-4-propyl-1,2-dihydropyridin-3-yl)methyl)-1H-indazole-4- Formula: C33H43N7O2 Molecular Weight: 569,74 g/mol CAS-No.: 1431612-23-5 Hazardous ingredients according to Regulation (EC) No 1272/2008 ComponentClassificationConcentration 1-isopropyl-6-(6-(4-isopropylpiperazin-1-yl)pyridin-3-yl)-N-((6-methyl-2-oxo-4-propyl-1,2- dihydropyridin-3-yl)methyl)-1H-indazole-4- CAS-No.1431612-23-5Acute Tox. 4; H302<= 100 % Hazardous ingredients according to Directive 1999/45/EC ComponentClassificationConcentration 1-isopropyl-6-(6-(4-isopropylpiperazin-1-yl)pyridin-3-yl)-N-((6-methyl-2-oxo-4-propyl-1,2- dihydropyridin-3-yl)methyl)-1H-indazole-4- CAS-No.1431612-23-5Xn, R22<= 100 % For the full text of the H-Statements and R-Phrases mentioned in this Section, see Section 16 SECTION 4: First aid measures Description of first aid measures General advice Consult a physician. Show this safety data sheet to the doctor in attendance. If inhaled If breathed in, move person into fresh air. If not breathing, give artificial respiration. Consult a physician. In case of skin contact Wash off with soap and plenty of water. Consult a physician. In case of eye contact Flush eyes with water as a precaution. If swallowed Never give anything by mouth to an unconscious person. Rinse mouth with water. Consult a physician. Most important symptoms and effects, both acute and delayed The most important known symptoms and effects are described in the labelling (see section 2.2) and/or in section 11 Indication of any immediate medical attention and special treatment needed no data available SECTION 5: Firefighting measures Extinguishing media Suitable extinguishing media Use water spray, alcohol-resistant foam, dry chemical or carbon dioxide. Special hazards arising from the substance or mixture Carbon oxides, nitrogen oxides (NOx) Advice for firefighters Wear self contained breathing apparatus for fire fighting if necessary. Further information no data available SECTION 6: Accidental release measures Personal precautions, protective equipment and emergency procedures Use personal protective equipment. Avoid dust formation. Avoid breathing vapours, mist or gas. Ensure adequate ventilation. Avoid breathing dust. For personal protection see section 8. Environmental precautions Do not let product enter drains. Methods and materials for containment and cleaning up Pick up and arrange disposal without creating dust. Sweep up and shovel. Keep in suitable, closed containers for disposal. Reference to other sections For disposal see section 13. SECTION 7: Handling and storage Precautions for safe handling Avoid contact with skin and eyes. Avoid formation of dust and aerosols. Provide appropriate exhaust ventilation at places where dust is formed. For precautions see section 2.2. Conditions for safe storage, including any incompatibilities Store in cool place. Keep container tightly closed in a dry and well-ventilated place. Recommended storage temperature: 2 - 8 °C Specific end use(s) A part from the uses mentioned in section 1.2 no other specific uses are stipulated SECTION 8: Exposure controls/personal protection Control parameters Components with workplace control parameters Exposure controls Appropriate engineering controls Handle in accordance with good industrial hygiene and safety practice. Wash hands before breaks and at the end of workday. Personal protective equipment Eye/face protection Safety glasses with side-shields conforming to EN166 Use equipment for eye protection tested and approved under appropriate government standards such as NIOSH (US) or EN 166(EU). Skin protection Handle with gloves. Gloves must be inspected prior to use. Use proper glove removal technique (without touching glove's outer surface) to avoid skin contact with this product. Dispose of contaminated gloves after use in accordance with applicable laws and good laboratory practices. Wash and dry hands. The selected protective gloves have to satisfy the specifications of EU Directive 89/686/EEC and the standard EN 374 derived from it. Body Protection Complete suit protecting against chemicals, The type of protective equipment must be selected according to the concentration and amount of the dangerous substance at the specific workplace. Respiratory protection For nuisance exposures use type P95 (US) or type P1 (EU EN 143) particle respirator.For higher level protection use type OV/AG/P99 (US) or type ABEK-P2 (EU EN 143) respirator cartridges. Use respirators and components tested and approved under appropriate government standards such as NIOSH (US) or CEN (EU). Control of environmental exposure Do not let product enter drains. SECTION 9: Physical and chemical properties Information on basic physical and chemical properties a) AppearanceForm: solid b) Odourno data available c) Odour Thresholdno data available d) pHno data available e) Melting point/freezingno data available point f) Initial boiling point and no data available boiling range g) Flash pointno data available h) Evapouration rateno data available i) Flammability (solid, gas) no data available j) Upper/lowerno data available flammability or explosive limits k) Vapour pressureno data available l) Vapour densityno data available m) Relative densityno data available n) Water solubilityno data available o) Partition coefficient: n- no data available octanol/water p) Auto-ignitionno data available temperature q) Decompositionno data available temperature r) Viscosityno data available s) Explosive propertiesno data available t) Oxidizing propertiesno data available Other safety information no data available SECTION 10: Stability and reactivity Reactivity no data available Chemical stability Stable under recommended storage conditions. Possibility of hazardous reactions no data available Conditions to avoid no data available Incompatible materials Strong oxidizing agents Hazardous decomposition products Other decomposition products - no data available In the event of fire: see section 5 SECTION 11: Toxicological information Information on toxicological effects Acute toxicity no data available Skin corrosion/irritation no data available Serious eye damage/eye irritation no data available Respiratory or skin sensitisation no data available Germ cell mutagenicity no data available Carcinogenicity IARC:No component of this product present at levels greater than or equal to 0.1% is identified as probable, possible or confirmed human carcinogen by IARC. Reproductive toxicity no data available Specific target organ toxicity - single exposure no data available Specific target organ toxicity - repeated exposure no data available Aspiration hazard no data available Additional Information RTECS: Not available To the best of our knowledge, the chemical, physical, and toxicological properties have not been thoroughly investigated. SECTION 12: Ecological information Toxicity no data available Persistence and degradability no data available Bioaccumulative potential no data available Mobility in soil no data available Results of PBT and vPvB assessment PBT/vPvB assessment not available as chemical safety assessment not required/not conducted Other adverse effects no data available SECTION 13: Disposal considerations Waste treatment methods Product Offer surplus and non-recyclable solutions to a licensed disposal company. Dissolve or mix the material with a combustible solvent and burn in a chemical incinerator equipped with an afterburner and scrubber. Contaminated packaging Dispose of as unused product. SECTION 14: Transport information UN number ADR/RID: -IMDG: -IATA: - UN proper shipping name ADR/RID: Not dangerous goods IMDG: Not dangerous goods IATA:Not dangerous goods Transport hazard class(es) ADR/RID: -IMDG: -IATA: - Packaging group ADR/RID: -IMDG: -IATA: - Environmental hazards ADR/RID: noIMDG Marine pollutant: noIATA: no Special precautions for user no data available SECTION 15 - REGULATORY INFORMATION N/A SECTION 16 - ADDITIONAL INFORMATION N/A |